Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Menopause

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

Disorders of the Female Reproductive System

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Hormonal Regulation of the Menstrual Cycle

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Mitral Valve Prolapse III: Nursing Management

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.

The Medical journal of Australia·2016

Same author

Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy.

The Medical journal of Australia·2016

Same author

Competency in menopause management: whither goest the internist?

Journal of women's health (2002)·2014

Same author

Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study.

Journal of the National Cancer Institute·2013

Same author

The perimenopausal woman: endocrinology and management.

The Journal of steroid biochemistry and molecular biology·2013

Same author

Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings: authors' response.

The journal of family planning and reproductive health care·2013

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

WHI risks: any relevance to menopause management?

Henry G Burger¹

¹Prince Henry's Institute & Jean Hailes Foundation For Women's Health, Clayton, Victoria, Australia. henry.burger@princehenrys.org

|March 21, 2007

Summary

Women's Health Initiative trials on hormone therapy (HT) found cardiovascular risks irrelevant for typical menopause management. Breast cancer risk requires careful consideration of prior HT use and therapy type.

Area of Science:

Reproductive Endocrinology
Cardiovascular Health
Oncology

Background:

The US Women's Health Initiative (WHI) conducted two randomized controlled trials on hormone therapy (HT).
Trials aimed to assess HT's impact on cardiovascular risk and breast cancer risk.
Participants were largely asymptomatic, postmenopausal, and some had prior HT use, influencing generalizability.

Purpose of the Study:

Critically evaluate the applicability of WHI findings to women prescribed HT for symptom relief.
Analyze cardiovascular and breast cancer risks separately for different patient profiles and HT regimens.
Determine the relevance of WHI results for conventional menopause management.

Main Methods:

Analysis of two large-scale, randomized controlled trials (Women's Health Initiative).

Related Experiment Videos

Last Updated: Jul 16, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Stratification of risks based on baseline characteristics (age, BMI, smoking, menopausal status).

Separate examination of cardiovascular and breast cancer outcomes in relation to HT use.

Main Results:

Cardiovascular risks observed in WHI trials are considered irrelevant for typical menopause management due to high-risk participants.
No increased breast cancer risk was found after five years of combined HT in women without prior HT use.
A trend towards decreased breast cancer risk was observed in individuals receiving estrogen-only therapy.

Conclusions:

WHI findings on cardiovascular disease are not directly applicable to symptomatic women undergoing short-term HT for menopause.
Breast cancer risk data from WHI is relevant, particularly for non-prior HT users and those on estrogen-only therapy.
Careful interpretation is needed when applying WHI results to diverse patient populations and HT indications.